- Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyoutSanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once tipped as potential blockbuster “would not represent a meaningful improvement” to existi…Fierce Biotech · 5h ago↗ source
- Gene editor Scribe starts second-half IPO spree with $129M listingA 9-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half. Scribe Therapeutics priced its $128.7 millionEndpoints · 8h ago↗ source
- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.